A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN7544, an Antagonist Monoclonal Antibody to NPR1, in Patients with Sepsis-Induced Hypotension
This research study is testing a new medicine, REGN7544, for adults who have very low blood pressure caused by sepsis, a severe reaction to an infection. When blood pressure drops too low, doctors often use other medicines called 'vasopressors' to help bring it back up. This study wants to find out if REGN7544 can reduce how much of these other medicines are needed, or if it can help patients recover without them. We will also check if REGN7544 is safe and how it moves through the body, by comparing it to a 'dummy' medicine (placebo). This is an early-stage study, meaning we are still learning a lot about this new treatment.
At a glance
What is this study about?
Sepsis is a very serious condition where your body's immune system overreacts to an infection, which can lead to organ damage and dangerously low blood pressure. When blood pressure drops too low, it's called 'sepsis-induced hypotension,' and it means your vital organs aren't getting enough blood. Doctors often use strong medicines called 'vasopressors' to help raise blood pressure in these situations.
This study is looking at a new medicine called REGN7544. It's an 'antagonist monoclonal antibody,' which is a type of targeted medicine that works by blocking a specific signal in the body. The main goal is to see if REGN7544 can help patients with sepsis-induced hypotension by reducing the amount of other blood pressure-raising medicines (vasopressors) they need. This could mean a smoother recovery and less strain on the body.
We also want to make sure REGN7544 is safe and to understand its effects. We'll be comparing it to a 'placebo,' which is a dummy medicine that looks just like REGN7544 but has no active ingredients. This helps us truly see if any changes or improvements are due to the new medicine or something else. Understanding how REGN7544 works and if it's safe for people with sepsis-induced hypotension is a really important step in finding new ways to treat this challenging condition.
Key takeaways
- New medicine (REGN7544) being tested for severe infection (sepsis) with very low blood pressure.
- Compares REGN7544 to a dummy medicine (placebo).
- Aims to see if REGN7544 reduces the need for other blood pressure medicines.
- Also checking for safety and how the body handles the medicine.
- Participants must be aged 18 or over.
- Both men and women can take part.
Who may be eligible?
To be able to join this study, you must be at least 18 years old. Both men and women can take part. The doctors will need to check if you have sepsis with very low blood pressure and if you meet other specific health requirements for the study.
There will be certain health conditions or treatments that might mean you can't join the study. These could include other serious illnesses, certain medications you're already taking, or if your doctors feel it's not safe for you to participate.
The research team will carefully review your medical history and current health to determine if this study is suitable for you. They will explain everything clearly, so you can understand if you meet the specific criteria to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with sepsis?
- Are you experiencing very low blood pressure due to sepsis?
- Are you currently receiving treatment for low blood pressure with a medicine called a 'vasopressor'?
What does participation involve?
If you decide to join this study, you would be given either the new medicine, REGN7544, or a matching dummy medicine (placebo) through a drip. Neither you nor your doctors would know which one you are receiving during the main part of the study.
The research team will closely monitor your health throughout the study. This will likely involve regular check-ups, blood tests to see how the medicine is working and how your body is reacting, and measurements of your blood pressure and other vital signs. They will also look for any side effects you might experience.
The total length of your participation would depend on your individual response and how long the researchers need to collect all the necessary information. There will also be follow-up visits or calls after the treatment period to ensure your continued well-being.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is sepsis?
Sepsis is a serious condition where your body's reaction to an infection damages its own tissues and organs. It can be life-threatening.
What does 'low blood pressure due to sepsis' mean?
It means the sepsis has caused your blood pressure to drop to dangerously low levels, which can stop organs from working properly.
What is a 'placebo'?
A placebo is a dummy medicine that looks exactly like the real medicine but contains no active ingredients. It helps researchers see if the real medicine is actually working.
Will I know if I'm getting the real medicine or the placebo?
No, this is a 'double-blind' study, meaning neither you nor your doctors will know whether you are receiving REGN7544 or the placebo until after the study is over, or at least a significant part of it.
Why is this study important?
This study is important because it could lead to new and better ways to treat critically ill patients suffering from sepsis and very low blood pressure, potentially saving lives and improving recovery.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.